GAITHERSBURG, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will host its 3rd annual Analyst and Investor Meeting on Tuesday, September 29, 2015 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
For additional information and registration, please email firstname.lastname@example.org or call 443-213-0506.
A live webcast link of the presentations will be available via the company website at novavax.com under “Investor Info”/ “Events”. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The event will be archived on the company's website for 90 days.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations email@example.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. firstname.lastname@example.org email@example.com 212-845-4271